Treating women carrying BRCA1 or BRCA2 mutations with PARP inhibitors to kill cancer cells before they grow into tumors is a new and hopeful concept in cancer prevention. However, the usefulness of this treatment relies on the fact that PARP1 inhibitors are completely non-toxic to humans.